RNS Number : 3886R IQ-AI Limited 28 February 2023 IQ-AI Announces Orphan Drug Designation Status FDA grants orphan status to Gallium Maltolate for treating GBM IQ-AI Limited, (LSE: IQAI) (OTCQB: IQAIF), is pleased to announce that the United States Food and Drug Administration (FDA) has granted orphan drug designation (ODD) status for gallium maltolate
RNS Number : 1496M IQ-AI Limited 10 January 2023 IQ-AI LIMITED ISSUES LETTER TO SHAREHOLDERS IQ-AI Limited (“IQAI”) (LSE: IQAI) (OTCQB: IQAIF) a developer and manufacturer of medical image processing platforms, has today released a letter to shareholders on behalf of Michael Schmainda, CEO of IQ-AI’s wholly-owned subsidiary Imaging Biometrics (the “Company”), covering several material recent
RNS Number : 4535I IQ-AI Limited 02 December 2022 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
RNS Number : 2244B IQ-AI Limited 30 September 2022 IQ-AI LIMITED ISSUES LETTER TO SHAREHOLDERS Imaging Biometrics, a subsidiary of IQ-AI Limited (OTCQB: IQAIF: LSE: IQAI), summarises the Company’s achievements in 2022 to date, which includes: · Company focuses on deployment of IB Clinic™ · IB NIMBLE™ connects experts to help treat metastatic
RNS Number : 5398A IQ-AI Limited 26 September 2022 26 September 2022 IQ-AI Limited (“IQ-AI” or the “Company”) Issue of Warrants to Employees IQAI Limited (the “Company” or “IQAI”), the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), which is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more
RNS Number : 1650W IQ-AI Limited 16 August 2022 16 August 2022 IQ-AI Limited (the “Company” or the “Group”) Half Yearly Report for the Period Ended 30 June 2022 Chief Executive’s Statement I am pleased to announce IQ-AI Limited’s unaudited financial results for the six months ended 30 June 2022. For further information, please
RNS Number : 8120U IQ-AI Limited 03 August 2022 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
RNS Number : 9294R IQ-AI Limited 11 July 2022 IQ-AI Limited (“IQ-AI” or the “Company”) Imaging Biometrics Announces Channel Partnership IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), is pleased to announce that its medical imaging analysis software, IB Clinic®, is now available via the newly launched Bayer Calantic platform. This latest distribution partnership
RNS Number : 2442N IQ-AI Limited 30 May 2022 30 May 2022 IQ-AI Limited (“IQ-AI” or the “Company”) Result of AGM IQ-AI Limited announces that at the annual general meeting of the Company held earlier today, all resolutions were duly passed. The Directors of the Company accept responsibility for the
RNS Number : 3069N IQ-AI Limited 31 May 2022 31 May 2022 IQ-AI Limited (“IQ-AI” or the “Company”) Imaging Biometrics Submits FDA 510(k) Application for IB Zero G Patented Artificial Intelligence Technology Eliminates the Need for Gadolinium-Based Contrast Agents in MRI Exams Milwaukee – 31 May 2022: Imaging Biometrics, LLC (IB), a
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.